Veracyte, a cancer diagnostics company, announced it will participate in the Canaccord Genuity Growth Conference in Boston on August 11 and the Morgan Stanley Global Healthcare Conference in New York on September 15, 2026. The company will hold fireside chats at both events, offering insights into its diagnostics platform and cancer care innovations. Live audio webcasts of the presentations will be available on Veracyte’s website, with replays accessible for 90 days. These events provide Veracyte an opportunity to engage investors and highlight its latest developments in molecular cancer diagnostics.
Argenx's stock surged 16.66% following positive Phase III ALKIVIA trial results for its autoimmune drug Vyvgart Hytrulo, showing significant efficacy in treating autoimmune myositis. Analyst firm William Blair reaffirmed an 'Outperform' rating, refle...
InspireMD reported better-than-expected Q2 results with a loss per share of -$0.17, improving from last year and beating estimates. Revenue reached $1.77 million, driven by strong 21% growth in international markets for its CGuard platform. The compa...
EyePoint Pharmaceuticals' stock dropped sharply after its wet AMD drug DURAVYU missed the primary trial endpoint, though an adjusted analysis showed it matched the standard treatment and cut treatment burden by 42%. Despite the setback, a Jefferies a...
H World Group reported better-than-expected Q2 2026 results, with earnings per share of $0.78 surpassing the $0.74 estimate and revenue of $1.05 billion exceeding forecasts. The company saw a 10.8% year-over-year revenue increase, driven mainly by a ...
Rocket Lab successfully launched eight satellites for MDA Space as part of a $143 million deal, boosting revenue to $234.07 million, above analyst expectations. Despite this operational success, the company reported a negative EPS of -$0.08, missing ...
